Top of this page
Skip navigation, go straight to the content
Welcome to our
Clinical Studies section
Development of new drugs
UCB researchers seek to understand, prevent and treat diseases.
Clinical studies involving healthy volunteers and patients play a vital role in the development of new drugs.
Patients are enrolled in clinical studies that are consistent with the principles that have their origin in the Declaration of Helsinki and its amendments as well as the laws, regulations and provisions of those countries where humans are enrolled.
Find out more about a selection of studies
Electroencephalographic neonatal seizures - "PETITE" Study – N01349
A Phase 2/3, Multicenter, Open-Label, Single-Arm Study to evaluate the Pharmacokinetics, Efficacy and Safety of Brivaracetam in Neonates with Repeated Electroencephalographic Seizures
Recruiting
Status
Immune Mediated Necrotizing Myopathy - IMNM01
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
Recruiting
Status
Systemic lupus erythematosus - "PHOENYCS GO" study - SL0043
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Recruiting
Status
Generalized Myasthenia Gravis - "RAISE" study - MG0009
A multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis.
Recruiting
Status
Chronic Inflammatory Diseases - "CHERISH" study - UP0085
A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
Recruiting
Status
Moderate to Severe Chronic Plaque Psoriasis - "CIMCare" study - PS0007
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Recruiting
Status
Hidradenitis Suppurativa - "Be Heard" study - HS0004
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
Status Hidradenitis Suppurativa - "Be Heard" study - HS0003
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
Status
Primary Immune Thrombocytopenia - "myOpportunITy 1" study - TP0003
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Recruiting
Status Primary Immune Thrombocytopenia - "myOpportunITy 2" study - TP0006
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Recruiting
Status
Myasthenia Gravis - "MycarinGStudy" - MG0003
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Recruiting
Status
Nonradiographic axial spondyloarthritis - "BE MOBILE 1" study - AS0010
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis.
Recruiting
Status
Ankylosing spondylitis - "BE MOBILE 2" study - AS0011
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis.
Recruiting
Status
Psoriatic arthritis - "BE OPTIMAL" study - PA0010
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis.
Recruiting
Status
Psoriatic arthritis - "BE COMPLETE" study - PA0011
A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis.
Recruiting
Status
Discover more about our clinical studies
Belgium
UCBCares.BE@ucb.com
+32 2 559 92 00
0800 38 008 (freephone)
www.ucbcares.be
Disease resources
